Peregrine Capital Management LLC decreased its holdings in ViewRay, Inc. (NASDAQ:VRAY – Get Rating) by 2.9% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,161,462 shares of the company’s stock after selling 35,284 shares during the period. Peregrine Capital Management LLC owned approximately 0.64% of ViewRay worth $5,203,000 as of its most recent SEC filing.
A number of other institutional investors also recently made changes to their positions in the business. BNP Paribas Arbitrage SNC boosted its stake in shares of ViewRay by 9.0% in the 3rd quarter. BNP Paribas Arbitrage SNC now owns 37,215 shares of the company’s stock valued at $135,000 after purchasing an additional 3,072 shares in the last quarter. Macquarie Group Ltd. boosted its position in ViewRay by 1.1% during the 2nd quarter. Macquarie Group Ltd. now owns 296,790 shares of the company’s stock valued at $786,000 after buying an additional 3,105 shares during the period. Metropolitan Life Insurance Co NY boosted its position in ViewRay by 70.8% during the 3rd quarter. Metropolitan Life Insurance Co NY now owns 8,954 shares of the company’s stock valued at $33,000 after buying an additional 3,713 shares during the period. Rockefeller Capital Management L.P. boosted its position in ViewRay by 82.0% during the 3rd quarter. Rockefeller Capital Management L.P. now owns 11,100 shares of the company’s stock valued at $40,000 after buying an additional 5,000 shares during the period. Finally, Bank of America Corp DE boosted its position in ViewRay by 2.4% during the 1st quarter. Bank of America Corp DE now owns 268,880 shares of the company’s stock valued at $1,054,000 after buying an additional 6,186 shares during the period. Hedge funds and other institutional investors own 84.40% of the company’s stock.
ViewRay Stock Down 1.9 %
Shares of NASDAQ VRAY opened at $3.55 on Friday. The company has a debt-to-equity ratio of 0.95, a quick ratio of 2.04 and a current ratio of 2.36. ViewRay, Inc. has a 12 month low of $2.39 and a 12 month high of $4.96. The firm has a fifty day simple moving average of $4.40 and a two-hundred day simple moving average of $4.26.
Wall Street Analysts Forecast Growth
Several brokerages have weighed in on VRAY. Oppenheimer reissued an “outperform” rating and set a $8.00 price target on shares of ViewRay in a research report on Tuesday, February 28th. StockNews.com began coverage on shares of ViewRay in a research report on Thursday. They set a “sell” rating for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $6.75.
ViewRay, Inc designs, manufactures and markets magnetic resonance imaging (MRI) system. It develops MRIdian to address the limitations of existing external-beam radiation therapy technologies, and employs MRI-based technology to provide real-time imaging that defines the tumor from the surrounding soft tissue, and other critical organs, both before and during radiation treatment delivery.
- Get a free copy of the StockNews.com research report on ViewRay (VRAY)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Want to see what other hedge funds are holding VRAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ViewRay, Inc. (NASDAQ:VRAY – Get Rating).
Receive News & Ratings for ViewRay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ViewRay and related companies with MarketBeat.com's FREE daily email newsletter.